Corey Marc Beausoleil, PA
Physician Assistant · Fairfield
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Northbay Physicians Surgery Center, LLC · Northbay Health Medical Foundation
Looking this up.
Hospitals listed: Northbay Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Corey Marc Beausoleil’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Northbay Medical CenterFairfield, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Northbay Healthcare, which runs 2 hospitalsPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.6 (11 to 18.8) · 166 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Northbay Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.6 (11 to 18.8) · 166 cases | Worse | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.08 (0.1 to 2.06) · 1,001 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.7 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 180.67 (132.84 to 228.51) · 88 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.7 · 31 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 171 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13 · 180 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.4 · 338 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 552 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.6 · 238 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 2,034 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,261 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.42) · 6,385 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.02 (1.87 to 6.16) · 1,179 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.89 (0.26 to 3.51) · 280 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.02 (0.51 to 3.54) · 1,156 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.55 (4.71 to 20.39) · 284 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (1.99 to 9.92) · 276 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.96 (0.48 to 3.43) · 256 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.34 (0 to 1) · 4,549 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 25 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.663 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.985 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.763 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.923 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.6 · 197 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 420 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 0.7 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 32.6 · 439 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25 · 627 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.8 · 560 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.7 to 7.9) · 166 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.9 · 210 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.1 (10.5 to 19) · 196 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 250 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,123 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$19,893
Medicare paid this office $19,893 for 51 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Fusion of upper spine bone with removal of disc and release of spinal cord or nerve, 1 disc | 15 | $2,708 | $181 |
| Insertion of cage or mesh device to spine bone and disc space during spine fusion | 24 | $1,323 | $28 |
| Placement of stabilizing device to back, 3-6 spine bone segments | 11 | $917 | $83 |
Procedures Medicare counted
| Laminectomy or laminotomy (partial removal of spine bones) | 29 | More than 59% of doctors who do this |
| Spinal fusion | 72 | More than 65% of doctors who do this |
Who their Medicare patients are
51 Original Medicare patients in 2024. Average age 71 · Women 45% · Also on Medicaid 41% · Health risk score 1.41. Above the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 75% · Diabetes 45% · Stroke 35% · Coronary heart disease 33% · Chronic kidney disease 33% · Depression 29% · Heart failure 25% · COPD 24%.
The office billed $547,301, Medicare allowed $24,924 and paid $19,893; for 259 services of 47 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 51 | 259 | 71 | 1.41 | $547,301 | $19,893 |
| 2023 | 68 | 230 | 72 | 1.23 | $418,795 | $17,086 |
| 2022 | 55 | 207 | 73 | 1.50 | $399,807 | $16,641 |
| 2021 | 15 | 36 | 75 | 1.21 | $62,669 | $3,073 |
| 2020 | 38 | 47 | 71 | 1.28 | $24,881 | $4,380 |
| 2019 | 47 | 81 | 72 | 1.66 | $99,825 | $7,023 |
| 2018 | 22 | 39 | 73 | 1.82 | $69,937 | $3,266 |
| 2017 | 28 | 43 | 72 | 1.92 | $64,619 | $3,722 |
| 2016 | 147 | 260 | 68 | 1.65 | $135,770 | $15,984 |
| 2015 | 122 | 185 | 68 | 1.24 | $135,634 | $13,503 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Insertion of cage or mesh device to spine bone and disc space during spine fusion | 15 | $748 | $29 |
2022: 1 service
| Insertion of cage or mesh device to spine bone and disc space during spine fusion | 12 | $642 | $38 |
2016: 7 services
| New patient visit (45+ min) | 47 | $4,303 | $92 |
| Short return visit (20+ min) | 39 | $1,992 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,505 | $44 |
| Return visit (30+ min) | 12 | $830 | $64 |
| X-ray of lower and sacral spine, minimum of 4 views | 20 | $592 | $30 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $411 | $26 |
| X-ray of upper spine, 4-5 views | 12 | $349 | $25 |
2015: 6 services
| New patient visit (45+ min) | 37 | $3,943 | $107 |
| Return visit (30+ min) | 16 | $1,114 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $664 | $47 |
| Short return visit (20+ min) | 12 | $562 | $47 |
| X-ray of lower and sacral spine, minimum of 4 views | 16 | $494 | $31 |
| X-ray of upper spine, 4-5 views | 12 | $339 | $28 |
Drugs they prescribed that Part D paid
$949
Pharmacies billed $949 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 48% of their Part D prescriptions (40 of 83) in 2024. A higher opioid share than 9 in 10 peers; the typical physician assistant clinician is at 1%.
81 generic and fewer than 11 brand-name prescriptions · $949 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Hydrocodone-Acetaminophen | 20 | $176 | $9 |
| Oxycodone-Acetaminophen | 13 | $130 | $10 |
| Cyclobenzaprine | 13 | $110 | $8 |
| Methocarbamol | 11 | $39 | $4 |
Year by year
| 2024 | 83 | 51 | 48% (40) | None | $949 |
| 2023 | 154 | 66 | 46% (70) | 0% | $1,807 |
| 2022 | 107 | 53 | 49% (52) | None | $1,150 |
| 2021 | 96 | 50 | 44% (42) | 0% | $800 |
| 2020 | 51 | 27 | 29% (15) | None | $802 |
| 2019 | 88 | 46 | 42% (37) | None | $1,493 |
| 2018 | 78 | 31 | 40% (31) | None | $1,776 |
| 2017 | 68 | 36 | 52% (35) | None | $1,607 |
| 2016 | 70 | 39 | 39% (27) | None | $1,190 |
| 2015 | 23 | 22 | 74% (17) | None | $626 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Oxycodone-Acetaminophen | 34 | $480 | $14 |
| Cyclobenzaprine | 47 | $361 | $8 |
| Hydrocodone-Acetaminophen | 30 | $275 | $9 |
2022: 2 drugs
| Hydrocodone-Acetaminophen | 38 | $369 | $10 |
| Cyclobenzaprine | 33 | $339 | $10 |
2021: 2 drugs
| Hydrocodone-Acetaminophen | 28 | $220 | $8 |
| Cyclobenzaprine | 23 | $130 | $6 |
2020: 1 drug
| Gabapentin | 14 | $259 | $18 |
2019: 2 drugs
| Hydrocodone-Acetaminophen | 23 | $181 | $8 |
| Cyclobenzaprine | 15 | $86 | $6 |
2018: 1 drug
| Hydrocodone-Acetaminophen | 16 | $214 | $13 |
2017: 1 drug
| Hydrocodone-Acetaminophen | 19 | $188 | $10 |
2016: 1 drug
| Gabapentin | 22 | $265 | $12 |
2015: 1 drug
| Hydrocodone-Acetaminophen | 11 | $139 | $13 |
Money from drug and device companies
$225 in 2025
| 2025 | 8 | 10 | None | $225 |
| 2024 | 12 | 25 | None | $882 |
| 2023 | 17 | 35 | None | $868 |
| 2022 | 13 | 28 | None | $604 |
| 2021 | 6 | 11 | None | $212 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Carlsmed | Aprevo | $94 | 3 payments
|
| SK Life Science | None | $28 | 1 payment
|
| EMD Serono | None | $21 | 1 payment
|
| Ucb | Fintepla | $19 | 1 payment
|
| Teva Pharmaceuticals USA | Austedo Xr | $18 | 1 payment
|
| Lilly USA | Kisunla | $17 | 1 payment
|
See all 10 published payments
| Tanabe Pharma America | Meals · 2025-12-03 | None | $14 |
| SK Life Science | Meals · 2025-11-12 | None | $28 |
| EMD Serono | Meals · 2025-11-06 | None | $21 |
| Ucb | Meals · 2025-10-17 | Fintepla | $19 |
| Carlsmed | Meals · 2025-09-09 | Aprevo | $27 |
| Teva Pharmaceuticals USA | Meals · 2025-09-08 | Austedo Xr | $18 |
| Carlsmed | Meals · 2025-06-13 | Aprevo | $36 |
| Carlsmed | Meals · 2025-05-28 | Aprevo | $31 |
| GlaxoSmithKline | Meals · 2025-04-22 | Nucala | $16 |
| Lilly USA | Meals · 2025-03-04 | Kisunla | $17 |
See earlier years (2024, 2023, 2022, 2021)
2024: $882
| AstraZeneca Pharmaceuticals LP | Andexxa | $283 | 5 payments
|
| Carlsmed | Aprevo | $248 | 5 payments
|
| Neurocrine Biosciences | Ingrezza | $109 | 4 payments
|
| SK Life Science | None | $51 | 2 payments
|
| Amneal Pharmaceuticals | Rytary | $39 | 2 payments
|
| Ge Healthcare | None | $31 | 1 payment
|
| Genentech USA | Ocrevus | $26 | 1 payment
|
| Eisai | Leqembi | $24 | 1 payment
|
| Becton Dickinson and | Arista Ah Flexitip | $20 | 1 payment
|
| Merz Pharmaceuticals | Xeomin | $20 | 1 payment
|
| Banner Life Sciences | Bafiertam | $16 | 1 payment
|
| Merck Sharp & Dohme | Bridion | $14 | 1 payment
|
2023: $868
| SK Life Science | None | $195 | 8 payments
|
| Argenx US | Vyvgart | $93 | 3 payments
|
| Pfizer | Panzyga | $86 | 3 payments
|
| Neurocrine Biosciences | Ingrezza | $65 | 2 payments
|
| Vanda Pharmaceuticals | Hetlioz | $60 | 2 payments
|
| CSL Behring | Hizentra | $53 | 2 payments
|
| Genzyme | Aubagio | $48 | 2 payments
|
| Amneal Pharmaceuticals | Rytary | $43 | 3 payments
|
| Lilly USA | Amyvid | $39 | 2 payments
|
| Ucb | Fintepla | $32 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | None | $30 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $28 | 1 payment
|
| Kyowa Kirin | Nourianz | $27 | 1 payment
|
| Integra LifeSciences | Codman Certas | $20 | 1 payment
|
| Chiesi USA | Cleviprex | $18 | 1 payment
|
| Lundbeck | Vyepti | $16 | 1 payment
|
| Genentech USA | Ocrevus | $14 | 1 payment
|
2022: $604
| Janssen Pharmaceuticals | Ponvory | $95 | 5 payments
|
| Amneal Pharmaceuticals | Rytary | $91 | 5 payments
|
| Integra LifeSciences | Codman Certas | $90 | 4 payments
|
| Lundbeck | Vyepti | $59 | 3 payments
|
| Genzyme | Aubagio | $43 | 2 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $42 | 2 payments
|
| Merz Pharmaceuticals | Xeomin | $37 | 1 payment
|
| SK Life Science | None | $31 | 1 payment
|
| Abbvie | Duopa | $30 | 1 payment
|
| 180 Medical | Cure Catheter | $28 | 1 payment
|
| Eisai | Fycompa | $21 | 1 payment
|
| Pacira Pharmaceuticals | Exparel | $19 | 1 payment
|
| Lilly USA | Amyvid | $18 | 1 payment
|
2021: $212
| Amneal Pharmaceuticals | Rytary | $60 | 3 payments
|
| Biogen | Aduhelm | $40 | 2 payments
|
| Amgen | Aimovig | $39 | 2 payments
|
| Genzyme | Aubagio | $30 | 2 payments
|
| Merz Pharmaceuticals | Xeomin | $22 | 1 payment
|
| AbbVie | Ubrelvy | $20 | 1 payment
|
Professional record
- NPI
- 1467846147
- Licence
- CA PA53605, NC 0010-05629
- Group
- Northbay Physicians Surgery Center, LLC · Northbay Health Medical Foundation
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2015-03-20
- NPI last updated
- 2020-12-04
- NPI record certified
- 2020-12-04
This is when the NPI record was last certified, not a medical board exam.